Latest news with #neuromodulation
Yahoo
5 days ago
- Business
- Yahoo
Jefferies Maintained a Buy Rating on LivaNova PLC (LIVN)
LivaNova PLC (NASDAQ:LIVN) is one of the . On June 6, Jefferies analyst Matthew Taylor maintained a Buy rating on LivaNova PLC (NASDAQ:LIVN) with a price target of $79. The analyst highlighted the company's strong growth potential driven by its solid product cycle. He noted the Essenz upgrade, which is expected to increase revenue by higher average selling prices as the replacement cycle advances. Moreover, Taylor also likes the company's expansion in the oxygenator market. He believes that the increasing market share and production capacity give LivaNova PLC (NASDAQ:LIVN) a competitive edge over its peers. A close-up of a medical device used for therapeutic solutions in a world-class hospital. He also points out the company's progress in Vagus Nerve Stimulation therapy for epilepsy, backed by strong long-term data. Taylor believes this strengthens its position in drug-resistant epilepsy treatment. LivaNova PLC (NASDAQ:LIVN) is a global medical technology company that designs and manufactures devices for cardiac surgery and neuromodulation. While we acknowledge the potential of LIVN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
23-07-2025
- Business
- Yahoo
electroCore to Announce Second Quarter June 30, 2025 Financial Results on Wednesday, August 6, 2025
ROCKAWAY, N.J., July 23, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial results for the second quarter ended June 30, 2025, after the close of the market on Wednesday, August 6, 2025. Management will host a webinar at 4:30 PM EDT to review the financial results and answer questions. Investors can access the webinar using the details below: Dial-In: (646) 931-3860Webinar ID: 843 8084 9004 Passcode: 049555Registration Link: Click here to participate and ask questions on the call. About electroCore, Inc. is a commercial stage bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company's two leading prescription products to treat chronic pain syndromes through non-invasive neuromodulation technology are gammaCore non-invasive vagus nerve stimulation (nVNS) and Quell neurostimulator. Additionally, the company commercializes its Truvaga products, handheld, and personal use nVNS products utilizing bioelectronic technologies, to promote general wellness and human performance. For more information, visit Contact ECOR Investor Relations(973) 302-9253investors@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
21-07-2025
- Business
- Globe and Mail
CVRx to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call on August 4, 2025
MINNEAPOLIS, July 21, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release second quarter 2025 financial and operating results after market close on Monday, August 4, 2025. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day. A live webcast of the investor conference call will be available online at the investor relations page of the Company's website at To listen to the conference call on your telephone, please dial 1-800-445-7795 for U.S. callers, or 1-785-424-1699 for international callers, approximately ten minutes prior to the start time. Please reference the following conference ID to access the call: CVRXQ225. About CVRx, Inc. CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit Investor Contact: Mark Klausner or Mike Vallie ICR Westwicke 443-213-0501 ir@ Media Contact: Emily Meyers CVRx, Inc. 763-416-2853 emeyers@
Yahoo
17-07-2025
- Health
- Yahoo
Saluda Medical Announces Full U.S. Launch of EVA™ Sensing Technology for Use with the Evoke® SmartLoop™ System
New Clinical Data on EVA to be Presented at ASPN 2025 Annual Conference MINNEAPOLIS, July 17, 2025 /PRNewswire/ -- Saluda Medical, Inc., a pioneer in the development and commercialization of a novel neuromodulation platform designed to transform the lives of patients with chronic neurological conditions, today announced the full commercial launch of EVA, its next-generation sensing technology, in the United States (U.S.). EVA received U.S. Food & Drug Administration (FDA) approval in December 2024 and is compatible with all commercially implanted Evoke® SmartLoop™ System patients. EVA, an extension of the Evoke System, objectively scans and analyzes a patient's spinal cord to deliver personalized therapy with precision beyond human capability. The Evoke SmartLoop System optimizes patient outcomes by sensing, measuring, and adjusting stimulation based on each patient's neural response biomarker, known as the evoked compound action potential (ECAP), to maintain therapy at the patient's prescribed level. "This full commercial launch represents a significant advancement in SCS therapy and delivers on the promise of objective dosing and more effective pain relief for patients," said Mike Mathias, Chief Commercial Officer at Saluda Medical. "In addition to its clinical benefits, EVA automates manual programming steps, thereby improving the patient experience. Since receiving FDA approval at the end of last year, EVA has been utilized in over 3,000 commercial patient visits through a limited market release." New clinical data to be presented at the American Society of Pain and Neuroscience (ASPN) 2025 Annual Conference, to be held July 17 – 20, 2025 in Miami, FL, will feature 11 abstracts and one oral presentation, which add to Saluda Medical's significant body of existing clinical evidence, including over 37 total publications. Among these are results from the landmark EVOKE Study, which demonstrated long-term efficacy out to 36-months. "The Evoke SmartLoop System with EVA provides objective dosing that enables more predictable and durable outcomes in SCS," said Jason Pope, MD, Founder and CEO, Evolve Restorative Center. "The data premiering at ASPN 2025 further demonstrates the compelling clinical benefits of the Evoke SmartLoop System, including increasing the diagnostic value of the trial phase and maintaining therapy response over time without loss of efficacy." About Saluda MedicalSaluda Medical is a commercial-stage medical device company focused on developing treatments for chronic neurological conditions using its novel neuromodulation platform. The Company's closed-loop, dose-control platform senses and measures neural responses to stimulation and automatically adjusts therapy based on real-time neurophysiological feedback. The Company's first product, the Evoke® System, is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain, and leg pain, and is designed to treat chronic neuropathic pain by providing spinal cord stimulation (SCS) therapy that senses and measures neural activation to optimize therapy and reduce patient and clinician burden. 12-month results from the EVOKE study, the first and only prospective, multi-center, parallel-arm, double-blind, randomized controlled pivotal study with a voluntary crossover arm in SCS, that demonstrated clinically superior pain relief to open-loop therapy, were published in The Lancet Neurology, 24-month results were published in JAMA Neurology, and 36-month data, that demonstrated sustained pain relief, were published in Regional Anesthesia and Pain Medicine. To learn more, including risks and important safety information, visit Saluda and Evoke are registered trademarks owned by Saluda Medical Pty Ltd. Investor Contacts: Brian Johnston or Sam Bentzingerbrian@ sam@ View original content to download multimedia: SOURCE Saluda Medical Sign in to access your portfolio
Globe and Mail
10-07-2025
- Business
- Globe and Mail
Is it Worth Adding Boston Scientific Stock to Your Portfolio Now?
Boston Scientific 's BSX robust MedSurg segment, driven by endoscopy, neuromodulation and urology businesses, is poised for further growth in the upcoming quarters. The long-term prospects of the WATCHMAN devices are also encouraging. The company's impressive strategic acquisitions provide a favorable opportunity for growth. Meanwhile, headwinds like currency fluctuations are concerning for its operations. In the past year, this Zacks Rank #2 (Buy) company's shares have rallied 33.6% compared with the industry and the S&P 500 composite's growth of 11.7% and 10.1%, respectively. The renowned manufacturer of medical devices and products has a market capitalization of $153.61 billion. BSX beat on earnings in each of the trailing four quarters, delivering an average surprise of 8.79%. Let us delve deeper. Upsides for BSX Stock MedSurg's Impressive Market Share Gain: Boston Scientific is consistently gaining market share within its MedSurg segment. The Endoscopy business within MedSurg is gaining from strong growth in endoluminal surgery and single-use imaging franchises, along with sustained growth of the AXIOS platform, where the company is reinvesting to drive expanded indications. Within Urology, Boston Scientific continues to expand market share globally. The company's Stone management and prostheticurology franchises are growing well, led by key launches with the TENACIO pump for the AMS 700 and continued success with the expanding LithoVue portfolio. Within Neuromodulation, Boston Scientific's pain and brain businesses are gaining traction. Within deep brain stimulation, the company expects to see improved growth in 2025, backed by the recent FDA and CE Mark approvals of the Cartesia X and HX leads. WATCHMAN, a Long-Term Growth Driver: Boston Scientific's structural heart programs are fast building momentum on the back of strong performance of the WATCHMAN left atrial appendage closure device. WATCHMAN is the first device to offer a non-pharmacologic alternative to oral anti-coagulants that has been studied in a randomized clinical trial and is the leading device in percutaneous LAAC globally. The next generation WATCHMAN FLX and FLX Pro are capturing the global market. In the first quarter of 2025, WATCHMAN sales increased 24% year over year, with a strong contribution from the rise in concomitant procedures enabled by the new DRG, which became effective in October. Impressive Value-Adding Acquisitions: Boston Scientific's recent acquisitions have added numerous products with immense potential. The company's recently completed strategic buyouts include Bolt Medical. Earlier, BSX had acquired Cortex, an advanced AF mapping solution. The company also acquired Silk Road to broaden in the field of vascular medicine. Boston Scientific also completed the acquisition of Axonics in the fourth quarter of 2024. Sales from closed acquisitions contributed 400 basis points in the first quarter, resulting in 18.2% organic revenue growth for Boston Scientific. The company is currently looking forward to close the acquisitions of SoniVie and Intera Oncology. Downside for BSX Stock Exposure to Currency Movement: With Boston Scientific recording 40% of its sales from the international market, it remains highly exposed to currency fluctuations. Unfavorable currency movements have been a major dampener over the past few quarters, as in the case of other important MedTech players. For 2025, the company expects a 50-basis point headwind from foreign exchange on revenues. BSX Stock's Estimate Trend The Zacks Consensus Estimate for 2025 earnings per share has remained unchanged at $2.91 in the past 30 days. The Zacks Consensus Estimate for 2025 revenues is pegged at $19.50 billion, indicating a 16.4% rise from the year-ago reported number. Other Key Picks Some other top-ranked stocks in the broader medical space are Align Technology ALGN, Abbott Laboratories ABT and Cencora COR. Align Technology has an estimated long-term earnings growth rate of 11.2% compared with the industry's 9.9%. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 3.4%. Its shares have lost 27.7% compared with the industry's 3.3% decline in the past year. ALGN carries a Zacks Rank #2 at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Abbott, currently carrying a Zacks Rank #2, has an earnings yield of 3.8% compared with the industry's 0.6%. Shares of the company have surged 129.7% compared with the industry's 35.9% gain. ABT's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 1.6%. Cencora, carrying a Zacks Rank #2 at present, has an earnings yield of 5.4% compared with the industry's 3.8%. Shares of the company have rallied 25.9% against the industry's 14.4% decline. COR's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6%. Higher. Faster. Sooner. Buy These Stocks Now A small number of stocks are primed for a breakout, and you have a chance to get in before they take off. At any given time, there are only 220 Zacks Rank #1 Strong Buys. On average, this list more than doubles the S&P 500. We've combed through the latest Strong Buys and selected 7 compelling companies likely to jump sooner and climb higher than any other stock you could buy this month. You'll learn everything you need to know about these exciting trades in our brand-new Special Report, 7 Best Stocks for the Next 30 Days. Download the report free now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report Cencora, Inc. (COR): Free Stock Analysis Report
